Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Post by crittergitteron Nov 07, 2012 6:54pm
279 Views
Post# 20574307

Best part of News Release:

Best part of News Release:

"The agreement provides Stem Cell Therapeutics with an option to an exclusive, world-wide license to an innovative cancer stem cell program."

https://cnrp.ccnmatthews.com/client/stem_cell_therapeutics/release.jsp?year=2012&actionFor=1688463&releaseSeq=0

Repeat after me: Ka-ching - Ka-ching - Ka-ching ~ Seriously, with six cents being the one year high, we should go through that like a hot-knife-through-butter tomorrow.

Bullboard Posts